The original Rh-negative breakthrough that has protected generations of babies.[1-4]

When you ask for RhoGAM...
make sure it's really RhoGAM

RhoGAM®
Ultra-Filtered PLUS
[Rh_0(D) Immune Globulin (Human)] (300 µg)

ACOG practice guidelines are based on clinical trials with the *One and Only RhoGAM*[5]

- #1 anti-D used in the US since 1968[1,6-9]
- Most recognized anti-D brand name
- A unique biologic with a proprietary manufacturing process[1]
- Longest half-life of any anti-D product, exceeding ACOG guidelines[5,7,10]
- Highly controlled plasma donor program at a single location[1]
- No human serum albumin (HSA) added[7]
- A rich heritage of continued innovation for over 50 years[7]
- Ready-to-use syringe eliminates preparation steps[7]
- No light protection required[7]
- ≈1 mL fill volume[1]
- Small, 22-gauge, 1¼" needle[1*]
- Safety Shield designed to protect from needlesticks[7]
- Only anti-D to offer product replacements[1]

*0.5 to 1.2 mL range. Each single-dose prefilled syringe contains 300 µg (1500 IU) of Rho(D) Immune Globulin (Human)

Indication

- RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 µg) and MicRhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (50 µg) are immune globulins indicated for use in preventing Rh immunization for pregnancy and other obstetrical conditions in Rh-negative women unless the father or baby is conclusively Rh-negative, e.g., delivery of an Rh-positive baby irrespective of the ABO groups of the mother and baby, any antepartum fetal-maternal hemorrhage (suspected or proven), actual or threatened pregnancy loss at any stage of gestation and ectopic pregnancy.

ANTI-D BRANDS ARE NOT ALL THE SAME... and vary in dosing, preparation, and administration requirements

Product	Approved[7]	Mean elimination half-life[7]	Plasma pool[1]	Ready-to-use?[7]	Dose/Formulation[7]	Storage[7]
RhoGAM® Ultra-Filtered PLUS [Rh_0(D) Immune Globulin (Human)] (300 µg)	1968	Intramuscular (IM): 30.9 days	Single dedicated collection facility	Yes	RhoGAM (1,500 IU) MicRhoGAM (250 IU)	2–8°C (36–46°F) No light restrictions

Product	Approved[8]	Mean elimination half-life[11]	Plasma pool[1]	Ready-to-use?[11]	Dose/Formulation[11]	Storage[11]
HyperRHO® S/D Mini-Dose (RhO[D] immune globulin [human])	2005	Intramuscular (IM): 23-26 days	No dedicated collection facility	Yes	Full Dose (1,500 IU) Mini Dose (250 IU)	2–8°C (36–46°F) No light restrictions

Product	Approved[9]	Mean elimination half-life[9]	Plasma pool[1]	Ready-to-use?[9]	Dose/Formulation[9]	Storage[9]
Rhophylac®, Rho(D), Immune Globulin Intravenous (Human)	2004	Intravenous (IV): 16 days Intramuscular (IM): 18 days	No dedicated collection facility	No (2-part syringe)	1,500 IU	2–8°C (36–46°F) Keep protected from light

RhoGAM helped set the standards and clinical practice guidelines that are still followed today[5]

ACOG practice guidelines are based on clinical trials with the One and Only RhoGAM[5]

RhoGAM®
Ultra-Filtered PLUS
[Rh_0(D) Immune Globulin (Human)] (300 µg)

Continue the legacy of protection

Make sure to only stock the Real RhoGAM

You can order RhoGAM through your Authorized Distributor or Kedrion Biopharma Customer Service

RhoGAM Ordering Information

NDC #	Description	Unit Measure	Quantity Level
0562-7805-01	RhoGAM Ultra-Filtered PLUS	EA	1 pack
0562-7805-05	RhoGAM Ultra-Filtered PLUS	EA	5 packs
0562-7805-25	RhoGAM Ultra-Filtered PLUS	EA	25 packs

Customer Service Contact Information

Phone: (855) 353-7466
Fax: (855) 751-7951
Email: US_CustomerService@kedrion.com
Hours: Mon-Fri 8:00AM - 6PM CT

Indication (cont.)

- In the case of postpartum use, RhoGAM and MicRhoGAM are intended for maternal administration. Do not inject the newborn infant.

Important Safety Information

- RhoGAM and MicRhoGAM are contraindicated in Rh-positive individuals and in patients with a known history of anaphylactic or severe systemic reactions to the administration of human immune globulin products.
- Severe hypersensitivity reactions may occur with the use of RhoGAM or MicRhoGAM. RhoGAM and MicRhoGAM should be administered in a setting where appropriate equipment, medications such as epinephrine, and personnel trained in the management of hypersensitivity, anaphylaxis, and shock are available.
- Products made from human blood may carry a risk of transmitting infectious agents (e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
- After administration of Rho(D) immune globulin, a transitory increase of various passively transferred antibodies in the patient's blood may yield positive serological testing results.
- The most frequently reported adverse reactions in patients receiving Rho(D) Immune Globulin (Human) products are injection site reactions, such as swelling, induration, redness and mild pain or warmth. Possible systemic reactions are skin rash, body aches or a slight elevation in temperature. Severe systemic reactions include allergic reactions and hemolytic reactions.
- **You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088. Please see accompanying RhoGAM and MicRhoGAM Full Prescribing Information.**

References: 1. Data on file. Kedrion Biopharma Inc. **2.** Bowman JM. The prevention of Rh immunization. *Transfus Med Rev*. 1988;2:129-150. **3.** Hartwell EA. Use of Rh immune globulin. ASCP practice parameter. *Am J Clin Pathol*. 1998;110:281-92. **4.** Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks' gestation service program. *Can Med Assoc J*. 1978;118:627-30. **5.** ACOG practice bulletin. Prevention of RhD Alloimmunization. Number 181, August 2017. *Obstet Gynecol*. 2017;130:e57-e70. **6.** The plasma proteins market in the United States, 2020. The Marketing Research Bureau. Orange, CT: 2021. **7.** RhoGAM Ultra-Filtered PLUS and MicRhoGAM® Ultra-Filtered PLUS [prescribing information]. Kedrion Biopharma Inc. 2019. **8.** HyperRHO S/D Full Dose. Product Monograph. Talecris Biotherapeutics. 2005. **9.** Rhophylac [prescribing information]. CSL Behring LLC. 2020. **10.** Aitken SL, Tichy EM. Rh D immune globulin products for prevention of alloimmunization during pregnancy. *Am J Health-Syst Pharm*. 2015;72:267-276. **11.** HyperRHO S/D Full Dose [prescribing information]. Grifols Therapeutics LLC. 2018.

KEDRION BIOPHARMA